{"entity":{"id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","aka":[],"tldr":"Rinzimetostat is an experimental small-molecule drug from ORIC Pharmaceuticals in phase 3 trials for prostate cancer, with its target not yet stated publicly.","summary":"Rinzimetostat (ORIC-944) is a small-molecule drug developed by ORIC Pharmaceuticals. The sponsor describes its target as PRC2 (EED subunit), which OnCo does not yet have a target page for. The sponsor states: A potent and selective allosteric inhibitor of Polycomb Repressive Complex 2 (PRC2) acting via the EED subunit, intended to provide advantages over EZH2-targeted approaches. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07723248 (A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)), in prostate cancer. The largest, NCT07723248, plans to enrol 600 participants with primary completion expected 2028-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Rinzimetostat","url":"https://clinicaltrials.gov/search?intr=ORIC-944"},{"label":"Sponsor pipeline page","url":"https://oricpharma.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["oric-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["himalayas-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"ORIC-944","modality":"small molecule","mechanism":"A potent and selective allosteric inhibitor of Polycomb Repressive Complex 2 (PRC2) acting via the EED subunit, intended to provide advantages over EZH2-targeted approaches.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rinzimetostat/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/"}],"trial":[{"id":"himalayas-1","kind":"trial","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","route":"/trials/himalayas-1/"}],"target":[{"id":"eed","kind":"target","name":"EED","route":"/targets/eed/"}]}}